Naka R, Tada K, Kaneko H, Nagata O, et al. Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (ritu Leuk Lymphoma 2022 Feb 2:1-4. doi: 10.1080/10428194.2022.2032040.
PMID: 35105261